JP2017526719A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526719A5 JP2017526719A5 JP2017513760A JP2017513760A JP2017526719A5 JP 2017526719 A5 JP2017526719 A5 JP 2017526719A5 JP 2017513760 A JP2017513760 A JP 2017513760A JP 2017513760 A JP2017513760 A JP 2017513760A JP 2017526719 A5 JP2017526719 A5 JP 2017526719A5
- Authority
- JP
- Japan
- Prior art keywords
- buprenorphine
- opioid
- pharmaceutical composition
- composition according
- formulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960001736 buprenorphine Drugs 0.000 claims 35
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 35
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 9
- 238000013270 controlled release Methods 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 7
- 239000007787 solid Substances 0.000 claims 7
- 241001539473 Euphoria Species 0.000 claims 6
- 206010015535 Euphoric mood Diseases 0.000 claims 6
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 4
- 230000000202 analgesic effect Effects 0.000 claims 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 4
- 229960002085 oxycodone Drugs 0.000 claims 4
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 3
- BCGJBQBWUGVESK-KCTCKCTRSA-N Oxymorphone hydrochloride Chemical compound Cl.O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BCGJBQBWUGVESK-KCTCKCTRSA-N 0.000 claims 3
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 3
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 3
- 229960000240 hydrocodone Drugs 0.000 claims 3
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 3
- 229960001410 hydromorphone Drugs 0.000 claims 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 3
- 229960005118 oxymorphone Drugs 0.000 claims 3
- 229960005374 oxymorphone hydrochloride Drugs 0.000 claims 3
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 3
- VDPLLINNMXFNQX-UHFFFAOYSA-N (1-aminocyclohexyl)methanol Chemical compound OCC1(N)CCCCC1 VDPLLINNMXFNQX-UHFFFAOYSA-N 0.000 claims 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 2
- BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 claims 2
- DYUTXEVRMPFGTH-UHFFFAOYSA-N 4-(2,5-dimethylphenyl)-5-methyl-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C(=CC=C(C)C=2)C)=C1C DYUTXEVRMPFGTH-UHFFFAOYSA-N 0.000 claims 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010011224 Cough Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 239000002585 base Substances 0.000 claims 2
- 229960004126 codeine Drugs 0.000 claims 2
- 229960002428 fentanyl Drugs 0.000 claims 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 2
- 229960002764 hydrocodone bitartrate Drugs 0.000 claims 2
- 229960002738 hydromorphone hydrochloride Drugs 0.000 claims 2
- 229960001797 methadone Drugs 0.000 claims 2
- 229960005181 morphine Drugs 0.000 claims 2
- 229940051877 other opioids in atc Drugs 0.000 claims 2
- 229960003617 oxycodone hydrochloride Drugs 0.000 claims 2
- 230000036407 pain Effects 0.000 claims 2
- 229960004380 tramadol Drugs 0.000 claims 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 2
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 claims 1
- JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical compound CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 claims 1
- UYTJNJSIWNXJIT-SSHYCOHZSA-N [(4R,4aS,7aR,12bS)-9-methoxy-3-methyl-7-oxo-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-4a-yl] tetradecanoate Chemical compound C(CCCCCCCCCCCCC)(=O)O[C@@]12CCC([C@H]3[C@]11C=4C(=C(C=CC=4C[C@H]2N(C)CC1)OC)O3)=O UYTJNJSIWNXJIT-SSHYCOHZSA-N 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 230000036592 analgesia Effects 0.000 claims 1
- 229960001889 buprenorphine hydrochloride Drugs 0.000 claims 1
- UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 229940002096 hydromorphone hydrochloride 2 mg Drugs 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229940058352 levulinate Drugs 0.000 claims 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 claims 1
- 229960001571 loperamide Drugs 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960003107 tramadol hydrochloride Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462049989P | 2014-09-12 | 2014-09-12 | |
| US62/049,989 | 2014-09-12 | ||
| US201462065393P | 2014-10-17 | 2014-10-17 | |
| US62/065,393 | 2014-10-17 | ||
| PCT/US2015/049948 WO2016040934A1 (en) | 2014-09-12 | 2015-09-14 | Systems and methods for attenuating opioid-induced euphoria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017526719A JP2017526719A (ja) | 2017-09-14 |
| JP2017526719A5 true JP2017526719A5 (enExample) | 2018-10-25 |
Family
ID=55453711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513760A Pending JP2017526719A (ja) | 2014-09-12 | 2015-09-14 | オピオイド誘発性多幸症を減弱するためのシステム及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20160074387A1 (enExample) |
| EP (1) | EP3190890A4 (enExample) |
| JP (1) | JP2017526719A (enExample) |
| KR (1) | KR20170052644A (enExample) |
| CN (1) | CN107072204A (enExample) |
| AU (1) | AU2015314714A1 (enExample) |
| CA (1) | CA2961009A1 (enExample) |
| IL (1) | IL251049A0 (enExample) |
| MA (1) | MA40333A (enExample) |
| TW (1) | TW201613590A (enExample) |
| WO (1) | WO2016040934A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018125716A1 (en) | 2017-01-02 | 2018-07-05 | Purdue Pharma L.P. | Morphinan derivatives and use thereof |
| CA3068036A1 (en) * | 2017-06-30 | 2019-01-03 | Purdue Pharma L.P. | Use to buprenorphine in combination with an opioid to treat pain |
| AU2018351502B2 (en) * | 2017-10-20 | 2024-09-05 | Purdue Pharma L.P. | Pharmaceutical dosage forms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1613266A4 (en) * | 2003-04-15 | 2009-05-06 | Theraquest Biosciences Llc | METHOD FOR TREATING PAIN AND COMPOSITIONS FOR USE THEREOF |
| EP1813276A1 (en) * | 2006-01-27 | 2007-08-01 | Euro-Celtique S.A. | Tamper resistant dosage forms |
| US20090246265A1 (en) * | 2008-03-26 | 2009-10-01 | Alltranz Inc. | Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists |
| WO2011109743A2 (en) * | 2010-03-04 | 2011-09-09 | Rand Jerry N | Synergistic effects of combinations of buprenorphine and opioids for the treatment of pain |
| CA2817071C (en) * | 2010-11-08 | 2018-04-24 | Omeros Corporation | Treatment of addiction and impulse-control disorders using pde7 inhibitors |
| HK1206978A1 (en) * | 2012-04-17 | 2016-01-22 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
-
2015
- 2015-09-11 TW TW104130183A patent/TW201613590A/zh unknown
- 2015-09-14 JP JP2017513760A patent/JP2017526719A/ja active Pending
- 2015-09-14 KR KR1020177009493A patent/KR20170052644A/ko not_active Withdrawn
- 2015-09-14 EP EP15840440.0A patent/EP3190890A4/en not_active Withdrawn
- 2015-09-14 CA CA2961009A patent/CA2961009A1/en not_active Abandoned
- 2015-09-14 WO PCT/US2015/049948 patent/WO2016040934A1/en not_active Ceased
- 2015-09-14 US US14/853,151 patent/US20160074387A1/en not_active Abandoned
- 2015-09-14 AU AU2015314714A patent/AU2015314714A1/en not_active Abandoned
- 2015-09-14 MA MA040333A patent/MA40333A/fr unknown
- 2015-09-14 CN CN201580055965.3A patent/CN107072204A/zh active Pending
-
2017
- 2017-03-09 IL IL251049A patent/IL251049A0/en unknown
-
2020
- 2020-03-24 US US16/828,350 patent/US20200276187A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2964022B1 (en) | Pain medicine combination and uses thereof | |
| ES2278647T3 (es) | Nuevos procedimientos y composiciones que comprenden opioides y antagonistas de opioides. | |
| JP2015514743A5 (enExample) | ||
| CA2782529C (en) | Morphinan derivatives for the treatment of drug overdose | |
| JP2011137020A5 (enExample) | ||
| RU2004106619A (ru) | Композиции опиоидного агониста, содержащие высвобождаемый и изолированный антагонист | |
| JP2011519930A5 (enExample) | ||
| JP6279547B2 (ja) | オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法 | |
| JP2016014040A5 (enExample) | ||
| WO2006138186A1 (en) | Two-component pharmaceutical composition for the treatment of pain | |
| RU2011104146A (ru) | Фармацевтическая композиция, содержащая опиоидный антагонист, для лечения задержки мочи | |
| WO2020055725A4 (en) | Dopamine d3 receptor selective antagonists/partial agonists and uses thereof | |
| JP2013537915A5 (enExample) | ||
| JP2021138703A (ja) | オピオイドとｎ−アシルエタノールアミンの組み合わせ | |
| JP2017526719A5 (enExample) | ||
| EA200870182A1 (ru) | Применение комбинации морфина и по меньшей мере одного антагониста опиатов для лечения зависимости от опиатов для предотвращения непероральной опиатомании у наркоманов | |
| JP2020533402A5 (enExample) | ||
| JP2015221794A5 (enExample) | ||
| US10874658B2 (en) | Sublingual opioid formulations containing naloxone | |
| JP2013505260A5 (enExample) | ||
| US10736874B1 (en) | Methods for treating pain associated with sickle cell disease | |
| CN102695508A (zh) | 阿片样受体拮抗剂用于胃肠道疾病的用途 | |
| WO2018204163A1 (en) | An opioid for use to reduce and/or treat drug addiction | |
| JP2005533046A5 (enExample) | ||
| CN114601819A (zh) | 一种水合氯醛在抑制阿片类药物复吸中的应用 |